Key statistics
On Monday, Beigene Ltd (688235:SHH) closed at 180.46, -1.92% below its 52-week high of 183.99, set on Sep 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 164.33 |
---|---|
High | 183.99 |
Low | 160.80 |
Bid | 180.46 |
Offer | 180.50 |
Previous close | 159.75 |
Average volume | 2.39m |
---|---|
Shares outstanding | 1.38bn |
Free float | 1.31bn |
P/E (TTM) | -- |
Market cap | 191.53bn CNY |
EPS (TTM) | -3.25 CNY |
Data delayed at least 15 minutes, as of Sep 30 2024 08:00 BST.
More ▼
Press releases
- BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
- Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
- BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
- BeiGene Announces Updates to Commercial Leadership Team
- BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
- BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
- BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
- BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
- BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
More ▼